S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:SESN

Sesen Bio - SESN News Today

$0.48
-0.02 (-3.13%)
(As of 10/5/2022 05:29 PM ET)
Add
Compare
Today's Range
$0.42
$0.49
50-Day Range
$0.38
$0.81
52-Week Range
$0.37
$1.47
Volume
1.19 million shs
Average Volume
3.09 million shs
Market Capitalization
$95.74 million
P/E Ratio
2.00
Dividend Yield
N/A
Price Target
N/A
Get Sesen Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for SESN and its competitors with MarketBeat's FREE daily newsletter.



SESN Media Mentions By Week

SESN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SESN
News Sentiment

0.62

0.80

Average
Medical
News Sentiment

SESN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SESN Articles
This Week

2

2

SESN Articles
Average Week

SourceHeadline
MarketBeat logoSesen Bio (NASDAQ:SESN) Earns Sell Rating from Analysts at StockNews.com
americanbankingnews.com - October 2 at 1:46 AM
finance.yahoo.com logoSESEN BIO, INC. (SESN) Stock Moves -0.43%: What You Should Know
finance.yahoo.com - September 30 at 12:13 AM
finance.yahoo.com logoThe Petri Dish: Embattled Sesen Bio shuts down via merger
finance.yahoo.com - September 22 at 7:01 AM
marketwatch.com logoSesen Bio Shares Sink After Merger News
marketwatch.com - September 21 at 3:56 PM
finance.yahoo.com logoNovartis, Moderna Partner Agrees To Merge With Beleaguered Sesen Bio
finance.yahoo.com - September 21 at 3:56 PM
marketwatch.com logoSesen Bio to Merge With Carisma Therapeutics
marketwatch.com - September 21 at 10:25 AM
markets.businessinsider.com logoSesen Bio, Carisma To Merge
markets.businessinsider.com - September 21 at 10:25 AM
seekingalpha.com logoSesen Bio in merger deal with immunotherapy company Carisma Therapeutics
seekingalpha.com - September 21 at 10:25 AM
finance.yahoo.com logoSesen Bio and Carisma Therapeutics Announce Merger Agreement
finance.yahoo.com - September 21 at 10:25 AM
finance.yahoo.com logoSESEN BIO, INC. (SESN) Dips More Than Broader Markets: What You Should Know
finance.yahoo.com - September 20 at 7:21 PM
finance.yahoo.com logoClovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer
finance.yahoo.com - September 14 at 3:11 PM
finance.yahoo.com logoIdeaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study
finance.yahoo.com - September 13 at 3:42 PM
finance.yahoo.com logoFDA Panel to Review Perrigo's (PRGO) OTC Birth Control Pill
finance.yahoo.com - September 13 at 3:42 PM
finance.yahoo.com logoAxsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study
finance.yahoo.com - September 9 at 3:24 PM
finance.yahoo.com logoAmylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug
finance.yahoo.com - September 9 at 3:24 PM
finance.yahoo.com logoGSK's NDA for Daprodustat to be Reviewed by an FDA Panel
finance.yahoo.com - September 7 at 4:57 PM
finance.yahoo.com logoSESEN BIO, INC. (SESN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
finance.yahoo.com - August 24 at 4:48 PM
finance.yahoo.com logoSanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down
finance.yahoo.com - August 17 at 3:38 PM
finance.yahoo.com logoEpizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
finance.yahoo.com - August 10 at 9:13 PM
finance.yahoo.com logoSesen Bio Reports Second Quarter 2022 Financial Results and Business Update
finance.yahoo.com - August 8 at 12:57 PM
finance.yahoo.com logoWhat's in the Cards for Sesen Bio's (SESN) Q2 Earnings?
finance.yahoo.com - July 27 at 3:25 PM
finance.yahoo.com logoSesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
finance.yahoo.com - July 19 at 5:51 PM
finance.yahoo.com logoSesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US
finance.yahoo.com - July 18 at 3:34 PM
nasdaq.com logoSesen Bio To Voluntarily Pause Further Development Of Vicineum In The US
nasdaq.com - July 18 at 10:34 AM
finance.yahoo.com logoSesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
finance.yahoo.com - July 18 at 10:34 AM
finance.yahoo.com logoF-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
finance.yahoo.com - June 24 at 12:41 PM
seekingalpha.com logoSesen Bio no longer seeks reverse stock split as route to regain compliance with Nasdaq
seekingalpha.com - June 17 at 5:35 PM
finance.yahoo.com logoGSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
finance.yahoo.com - June 13 at 3:23 PM
finance.yahoo.com logoFDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy
finance.yahoo.com - June 13 at 3:23 PM
benzinga.com logoSesen Bio (NASDAQ:SESN), Short Interest Report
benzinga.com - June 13 at 5:20 AM
finance.yahoo.com logoFDA Committee Recommends bluebird's (BLUE) CALD Therapy
finance.yahoo.com - June 10 at 5:40 PM
finance.yahoo.com logoBMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
finance.yahoo.com - June 3 at 9:22 PM
seekingalpha.com logoSesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
seekingalpha.com - June 2 at 5:48 PM
finance.yahoo.com logoRepare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug
finance.yahoo.com - June 2 at 5:48 PM
finance.yahoo.com logoBioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
finance.yahoo.com - June 1 at 4:35 PM
finance.yahoo.com logoAxcella (AXLA) Up on Decision to Prioritize Long-COVID Program
finance.yahoo.com - May 27 at 3:26 PM
finance.yahoo.com logoMerck (MRK) Keytruda Gets EU Nod for Expanded Breast Cancer Use
finance.yahoo.com - May 25 at 10:36 AM
finance.yahoo.com logoPfizer (PFE) Reports More Positive Data From Etrasimod Study
finance.yahoo.com - May 25 at 10:36 AM
finance.yahoo.com logoMerck (MRK) Outperforms Industry This Year So Far: Here's Why
finance.yahoo.com - May 19 at 4:03 PM
finance.yahoo.com logoAbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug
finance.yahoo.com - May 17 at 4:07 PM
finance.yahoo.com logoChimerix (CMRX) Plunges on Unfavorable Pipeline Updates
finance.yahoo.com - May 17 at 11:06 AM
finance.yahoo.com logoLilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
finance.yahoo.com - May 16 at 3:03 PM
finance.yahoo.com logoSesen Bio Reports First Quarter 2022 Financial Results and Business Update
finance.yahoo.com - May 9 at 8:59 AM
seekingalpha.com logoSesen Bio gains on plans to explore strategic options including a sale
seekingalpha.com - May 3 at 9:45 AM
finance.yahoo.com logoSesen Bio Provides Strategic Update
finance.yahoo.com - May 3 at 9:45 AM
seekingalpha.com logoSesen Bio updates on resubmission plans for Vicineum marketing application
seekingalpha.com - March 31 at 11:29 AM
finance.yahoo.com logoSesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
finance.yahoo.com - February 28 at 12:44 PM
nasdaq.com logoNotable Tuesday Option Activity: UIS, SESN, BLNK
nasdaq.com - February 22 at 5:29 PM
finance.yahoo.com logoIs Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - February 17 at 5:25 PM
nasdaq.com logoSesen Bio (NASDAQ:SESN) shareholders have endured a 75% loss from investing in the stock a year ago
nasdaq.com - February 14 at 5:52 PM
Get Sesen Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for SESN and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:SESN) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.